Efficacy of sublingual vectorized recombinant Bet v 1a in a mouse model of birch pollen allergic asthma

We demonstrate in a murine model of chronic BP respiratory allergy the efficacy of SLIT with vectorized rBet v 1a. Thus, combining recombinant allergens with mucoadhesive vector systems paves the ground for improved second generation sublingual allergy vaccines.